Commercial Large Language Models Enter a High-Stakes Dermatologic Setting
An authors’ reply in Clinical Infectious Diseases centers on a narrow but clinically sensitive question: how well commercial large language models perform when asked to interpret images of anogenital skin lesions. The topic sits at the intersection of infectious diseases, dermatology, and AI-assisted triage, where image interpretation can influence whether a patient is reassured, tested, treated, or referred for urgent evaluation.
Anogenital lesions are not a single disease category. They can represent sexually transmitted infections, inflammatory dermatoses, benign skin findings, neoplasia, or trauma-related changes, and the same visual pattern may carry very different implications depending on location, morphology, symptoms, immune status, and sexual history. In that setting, any diagnostic system built from images alone faces an immediate challenge: the appearance of a lesion is only one fragment of the clinical picture.
The title alone signals a central tension in digital medicine. Commercial large language models are being tested in a domain where misclassification can carry consequences well beyond academic error. A false reassurance can delay treatment for a transmissible infection; a false alarm can trigger unnecessary anxiety, testing, or referral. In the anogenital region, where embarrassment and delayed presentation are common, the stakes are even higher because patients may already arrive late in the course of disease.
Why Image-Only Interpretation Is a Difficult Fit for Anogenital Disease
Image-based assessment works best when the disease has a highly stereotyped visual signature. The anogenital region rarely offers that luxury. Moisture, friction, excoriation, coexisting dermatoses, and post-inflammatory change can all blur the visual field. A lesion that appears subtle on one image may be clinically obvious in person, while a dramatic-looking erythematous patch may turn out to be nonspecific irritation.
Large language models also raise a category problem. These systems are designed to process and generate language, yet commercial platforms increasingly extend into image interpretation. In a task like anogenital lesion recognition, performance depends not only on whether the model can “see” a lesion, but whether it can integrate lesion morphology, anatomical site, and clinical context in a way that resembles bedside reasoning. Human clinicians do that continuously, often by comparing visual findings with symptom tempo, exposure history, and exam details that never appear in an isolated image.
A lesion is not a diagnosis.
That gap matters most in infection-related care. Herpetic vesicles, condylomatous lesions, syphilitic plaques, molluscum, candidal changes, and noninfectious rashes can overlap visually enough to confound even experienced observers, especially when images are low resolution or partially obscured. In practice, diagnosis often depends on pattern recognition plus a structured history, targeted examination, and confirmatory testing. Any AI system evaluated in this space has to be judged against that clinical reality rather than against image recognition alone.
Commercial AI and the Problem of Clinical Context
Commercial AI tools are increasingly marketed as general-purpose decision aids, but generality can become a weakness when the target domain is anatomically and diagnostically specialized. The anogenital area is a case in point. The location itself changes the pretest probability of sexually transmitted infection, inflammatory disease, or local trauma, and it also changes the threshold for in-person assessment because patient discomfort, stigma, and public health implications can all be present at once.
Diagnostic accuracy in this context is not merely a technical metric. It determines whether AI output could realistically function as a triage layer, a second opinion, or a patient-facing informational tool. If the system produces vague or overly confident answers, it risks being worse than unhelpful. If it performs well only under tightly controlled conditions, its value may be limited when applied to the messy reality of outpatient care, urgent care, or teledermatology encounters.
The title also suggests the continuing need for direct academic scrutiny of commercial models rather than assumption-driven adoption. In areas with visible lesions and emotionally charged concerns, product claims can move faster than validation. The response from investigators in the medical literature keeps the conversation anchored to diagnostic performance, not marketing language.
What Clinicians Need from AI in This Space
For clinicians, the practical question is not whether a large language model can generate a plausible diagnosis. It is whether the model can safely narrow the differential, identify cases needing urgent in-person review, and avoid false certainty when the visual signal is ambiguous. In anogenital disease, safe performance would require a bias toward caution, clear acknowledgment of uncertainty, and recognition that image-only evaluation cannot replace a proper examination.
The same logic applies to patients using consumer AI tools before seeking care. A system that overcalls a benign lesion may intensify anxiety and contribute to unnecessary stigma. A system that undercalls a clinically meaningful lesion may delay diagnosis of conditions that are transmissible, progressive, or malignancy-associated. Either error path has consequences that extend beyond the screen.
Because the available text is limited to the article title, the correspondence appears to be part of an ongoing scientific exchange rather than a full standalone trial report. Even so, the subject itself is clinically important. Anogenital lesions demand careful differential diagnosis, and commercial AI systems must be tested against that standard with transparency about failure modes, not just overall accuracy summaries.
The Diagnostic Bar Remains High
An evaluation of commercial large language models in this setting belongs to a broader effort to define where AI can responsibly support infectious disease and dermatologic care. The bar is high because the clinical problem is high stakes, visually variable, and context dependent. In the wrong hands, a tool that seems helpful can become a source of diagnostic drift.
The most important unresolved issue is not whether these systems can produce an answer. It is whether the answer is reliable enough to influence care in a domain where anatomy, sexual health, and infection risk converge. Until validation is anchored to real clinical use, anogenital lesion images will remain a stringent test of whether commercial AI can move from fluent text generation to trustworthy medical reasoning.